Third Pole Therapeutics, a US-based privately held company that says it is developing critical life-sustaining cardio-pulmonary therapies, announced on Thursday that it is presenting at the H.C. Wainwright BioConnect 2022 Conference and participating in BIO Partnering at JPM.

All events are virtual and scheduled concurrently with the J.P. Morgan 40th Annual Healthcare Conference.

Details of the events and presentation are as follows: H.C. Wainwright BioConnect 2022 Conference January 10-13, On-demand presentation available starting on Monday, January 10th at 07:00 hours ET, Virtual Webcast.

BIO Partnering at JPM, 10-14 January, registration at https://www.bio.org/events/bio-partnering-jpm.

During the events, Third Pole management will provide an update on the company's financing and development of a miniaturised, wearable device designed to generate nitric oxide from air and electricity (iNO). This device is claimed to create a revolutionary advantage that will dramatically expand inhaled nitric oxide therapy by making it practical to treat a wide variety of life-limiting cardiopulmonary diseases in any setting, including the more than 1.2M patients struggling at home with severe COPD and ILD (e.g., pulmonary fibrosis).

CEO Bill Athenson will present recent business and clinical development activities and anticipated milestones during the H.C. Wainwright BioConnect Conference. Athenson will also be available for virtual one-on-one meetings with registered investors and pharmaceutical companies at BIO Partnering at JPM.